Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LCAR-HL30

Cell therapy · Kills target cells

Phase 1 Most advanced trial
1 Registered trials

What is LCAR-HL30?

LCAR-HL30 is an engineered cell therapy given after a conditioning regimen of cyclophosphamide and fludarabine. It is studied in Hodgkin lymphoma and anaplastic large cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Mechanism
Kills target cells
Therapy area
Oncology
In trials of
LEGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06494371 Phase 1 Hodgkin's Lymphoma Recruiting LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anaplastic Large Cell LymphomaHodgkin's Lymphoma

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.